2022
DOI: 10.1016/j.braindev.2022.02.005
|View full text |Cite
|
Sign up to set email alerts
|

Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 10 publications
0
3
0
Order By: Relevance
“…It has been established that underlying neuropathology, seizure types, and the administration of ASMs can all have major impact on patients' cognitive abilities ( 47 ). Lacosamide is well tolerated and may have potentially positive effects on social, behavioral, and motor function while controlling seizures in children with epilepsy ( 48 54 ). Grosso et al recruited 8 children (aged 8–16) with epileptic syndromes who had continuous spike and waves during slow sleep in a study.…”
Section: Effects Of Lacosamide Treatment On the Cognitive And Behavio...mentioning
confidence: 99%
“…It has been established that underlying neuropathology, seizure types, and the administration of ASMs can all have major impact on patients' cognitive abilities ( 47 ). Lacosamide is well tolerated and may have potentially positive effects on social, behavioral, and motor function while controlling seizures in children with epilepsy ( 48 54 ). Grosso et al recruited 8 children (aged 8–16) with epileptic syndromes who had continuous spike and waves during slow sleep in a study.…”
Section: Effects Of Lacosamide Treatment On the Cognitive And Behavio...mentioning
confidence: 99%
“…The drug showed meaningful efficacy with >80% of the children achieving seizure freedom finally and no severe adverse effects during the study period. However, limitations of the study 16 include its relatively small sample size and lack of insight into cognition and EEG.…”
Section: Introductionmentioning
confidence: 99%
“…It is commonly administrated in patients with epilepsy and occasionally in patients with trigeminal neuralgia or other neuropathic pain [ 1 , 5 , 7 , 8 , 9 , 10 , 11 , 12 ]. A growing body of evidence demonstrated the effectiveness and tolerability of LCS in patients with epilepsy [ 13 , 14 , 15 , 16 , 17 , 18 , 19 ]. Earlier reports have shown that this compound can decrease the frequency of interictal spikes as well as high-frequency oscillations in mesial temporal lobe epilepsy or refractory focal epilepsy [ 13 , 20 ].…”
Section: Introductionmentioning
confidence: 99%